NYSE:LH - Laboratory Corp. of America Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$145.22 +1.06 (+0.74 %)
(As of 04/18/2019 04:00 PM ET)
Previous Close$144.16
Today's Range$142.93 - $147.77
52-Week Range$119.38 - $190.35
Volume1.37 million shs
Average Volume818,917 shs
Market Capitalization$14.33 billion
P/E Ratio13.18
Dividend YieldN/A
Beta1.15
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides technology-enabled solutions, including a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with convenient and secure access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP50540R40
Phone336-229-1127

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.33 billion
Cash Flow$15.2222 per share
Book Value$69.09 per share

Profitability

Net Income$883.70 million

Miscellaneous

Employees61,000
Market Cap$14.33 billion
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) announced its quarterly earnings results on Thursday, February, 7th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.48 by $0.04. The medical research company had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. Laboratory Corp. of America had a net margin of 8.43% and a return on equity of 17.05%. The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.45 earnings per share. View Laboratory Corp. of America's Earnings History.

When is Laboratory Corp. of America's next earnings date?

Laboratory Corp. of America is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for Laboratory Corp. of America.

What guidance has Laboratory Corp. of America issued on next quarter's earnings?

Laboratory Corp. of America issued an update on its FY19 earnings guidance on Thursday, February, 7th. The company provided EPS guidance of $11.00-11.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.22. The company issued revenue guidance of +0.5-2.5% to approximately $11.38-11.61 billion, compared to the consensus revenue estimate of $11.52 billion.Laboratory Corp. of America also updated its FY 2019 guidance to $11.00-11.40 EPS.

What price target have analysts set for LH?

18 brokers have issued twelve-month target prices for Laboratory Corp. of America's stock. Their forecasts range from $155.00 to $193.00. On average, they anticipate Laboratory Corp. of America's stock price to reach $175.50 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Laboratory Corp. of America.

What is the consensus analysts' recommendation for Laboratory Corp. of America?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Corp. of America in the last year. There are currently 2 sell ratings, 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Laboratory Corp. of America.

What are Wall Street analysts saying about Laboratory Corp. of America stock?

Here are some recent quotes from research analysts about Laboratory Corp. of America stock:
  • 1. According to Zacks Investment Research, "LabCorp exited the fourth quarter on a promising note with better-than-expected earnings and revenues. Acquisitions and organic volume expansion positively contributed to LabCorp Diagnostics business in the last-reported quarter. This apart, Covance Drug Development has reported sturdy growth. This uptrend was primarily owing to strategic acquisitions and robust organic growth. On the flip side, in the quarter, the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth. According to the company, in Diagnostics, the fourth quarter was burdened with a number of non-operational items causing a 400 basis point decline in the operating margin. The company strongly expects 2019 to continue to witness similar hurdles. LabCorp has underperformed its industry in the past three months." (2/11/2019)
  • 2. Canaccord Genuity analysts commented, "We lower our estimates and PT from $162 to $155, which now uses a 13.8x multiple on our lower ’19 Adj. EPS of $11.30." (12/2/2018)

Has Laboratory Corp. of America been receiving favorable news coverage?

News coverage about LH stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Laboratory Corp. of America earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term.

Who are some of Laboratory Corp. of America's key competitors?

What other stocks do shareholders of Laboratory Corp. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Corp. of America investors own include CA (CA), BlackRock (BLK), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Amgen (AMGN), Allergan (AGN), Cisco Systems (CSCO), NVIDIA (NVDA) and Gilead Sciences (GILD).

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the folowing people:
  • Mr. David P. King, Chairman, CEO & Pres (Age 63)
  • Mr. Glenn A. Eisenberg, CFO & Exec. VP (Age 58)
  • Mr. F. Samuel Eberts III, Chief Legal Officer, Chief Compliance Officer, Sr. VP & Sec. (Age 59)
  • Mr. John D. Ratliff, Chief Exec. Officer of Covance Drug Devel. (Age 59)
  • Dr. Michelle Abelson, Laboratory Director of Operations

Who are Laboratory Corp. of America's major shareholders?

Laboratory Corp. of America's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.61%), Global Thematic Partners LLC (0.52%), State of Alaska Department of Revenue (0.07%), Mcrae Capital Management Inc. (0.07%), Baltimore Washington Financial Advisors Inc. (0.06%) and Cohen Klingenstein LLC (0.05%). Company insiders that own Laboratory Corp. of America stock include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, M Huff Gary and R Sanders Williams. View Institutional Ownership Trends for Laboratory Corp. of America.

Which major investors are selling Laboratory Corp. of America stock?

LH stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, QUANTRES ASSET MANAGEMENT Ltd, Douglass Winthrop Advisors LLC, DNB Asset Management AS, Raymond James Trust N.A., Daiwa SB Investments Ltd., Retirement Systems of Alabama and BTIM Corp.. Company insiders that have sold Laboratory Corp. of America company stock in the last year include David P King, Edward T Dodson, Glenn A Eisenberg, Kerrii B Anderson, Lisa J Uthgenannt, M Huff Gary and R Sanders Williams. View Insider Buying and Selling for Laboratory Corp. of America.

Which major investors are buying Laboratory Corp. of America stock?

LH stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Cohen Klingenstein LLC, Triangle Securities Wealth Management, Triad Investment Management, Calamos Wealth Management LLC, Global Thematic Partners LLC, Weybosset Research & Management LLC and Mercer Global Advisors Inc. ADV. View Insider Buying and Selling for Laboratory Corp. of America.

How do I buy shares of Laboratory Corp. of America?

Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of LH stock can currently be purchased for approximately $145.22.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $14.33 billion and generates $11.33 billion in revenue each year. The medical research company earns $883.70 million in net income (profit) each year or $11.02 on an earnings per share basis. Laboratory Corp. of America employs 61,000 workers across the globe.

What is Laboratory Corp. of America's official website?

The official website for Laboratory Corp. of America is http://www.labcorp.com.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]


MarketBeat Community Rating for Laboratory Corp. of America (NYSE LH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  448 (Vote Outperform)
Underperform Votes:  483 (Vote Underperform)
Total Votes:  931
MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe LH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel